{"id":"macugen-pegaptanib-sodium","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Photopsia (flashing lights)"},{"rate":null,"effect":"Anterior chamber inflammation"}]},"_chembl":{"chemblId":"CHEMBL1201421","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegaptanib is a pegylated aptamer—a short, single-stranded DNA molecule—that selectively binds to VEGF165, a key isoform of vascular endothelial growth factor. By neutralizing VEGF, it suppresses neovascularization and vascular permeability in the retina, slowing vision loss in age-related macular degeneration. It is administered as an intravitreal injection.","oneSentence":"Pegaptanib is an aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:41.303Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"}]},"trialDetails":[{"nctId":"NCT00790803","phase":"NA","title":"Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2009-03","conditions":"Uveitis, Cystoid Macular Edema","enrollment":5},{"nctId":"NCT01573572","phase":"PHASE4","title":"Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-04-22","conditions":"Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema","enrollment":131},{"nctId":"NCT00549055","phase":"","title":"A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Neovascular Age-related Macular Degeneration","enrollment":38},{"nctId":"NCT00605280","phase":"PHASE2, PHASE3","title":"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Macular Edema Associated With Diabetes Mellitus","enrollment":317},{"nctId":"NCT02321267","phase":"PHASE4","title":"Cohort Study of the Clinical Course of Macular Diseases in Kagawa","status":"UNKNOWN","sponsor":"Kagawa University","startDate":"2014-12","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT02081339","phase":"","title":"Cohort Study of the Clinical Course of Macular Diseases in Japanese","status":"UNKNOWN","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2014-03","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT00242580","phase":"PHASE3","title":"A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":111},{"nctId":"NCT00845273","phase":"","title":"Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Macular Degeneration","enrollment":3538},{"nctId":"NCT01218230","phase":"NA","title":"Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia","status":"WITHDRAWN","sponsor":"L.V. Prasad Eye Institute","startDate":"2010-12","conditions":"Myopic Choroidal Neovascular Membrane","enrollment":""},{"nctId":"NCT01281098","phase":"PHASE2","title":"Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2010-03","conditions":"High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I, Diabetes Mellitus Type II","enrollment":22},{"nctId":"NCT00320775","phase":"PHASE1","title":"Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2005-06","conditions":"Macular Degeneration","enrollment":51},{"nctId":"NCT00820742","phase":"","title":"Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2008-02","conditions":"Neovascular Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT01175070","phase":"PHASE4","title":"Intravitreal Macugen for Ischaemic Diabetic Macular Oedema","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-01","conditions":"Diabetic Macular Oedema","enrollment":30},{"nctId":"NCT00709657","phase":"NA","title":"The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2008-03","conditions":"Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor","enrollment":8},{"nctId":"NCT00406107","phase":"PHASE4","title":"Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Palmetto Retina Center, LLC","startDate":"2006-01","conditions":"Branch Retinal Vein Occlusion","enrollment":20},{"nctId":"NCT01589718","phase":"PHASE3","title":"A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy","status":"WITHDRAWN","sponsor":"Greater Houston Retina Research","startDate":"2012-04","conditions":"Proliferative Diabetic Retinopathy","enrollment":""},{"nctId":"NCT01189461","phase":"PHASE3","title":"Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-01","conditions":"Anti- VGF Inhibitor, Diabetic Macular Edema, Diabetic Retinopathy","enrollment":46},{"nctId":"NCT01100307","phase":"PHASE3","title":"A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-05","conditions":"Macular Edema, Diabetic Mellitus, Retinal Disease","enrollment":243},{"nctId":"NCT01486238","phase":"PHASE4","title":"Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study","status":"COMPLETED","sponsor":"Valley Retina Institute","startDate":"2009-04","conditions":"Diabetic Macular Edema","enrollment":72},{"nctId":"NCT00460408","phase":"","title":"Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-08","conditions":"Macular Degeneration","enrollment":501},{"nctId":"NCT00446381","phase":"NA","title":"Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2006-10","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":28},{"nctId":"NCT00858208","phase":"","title":"Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03","conditions":"Neovascular Age-related Macular Degeneration","enrollment":86},{"nctId":"NCT00327470","phase":"PHASE4","title":"An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-07","conditions":"Age Related Macular Degeneration (AMD), Macular Degeneration, Choroidal Neovascularization (CNV)","enrollment":288},{"nctId":"NCT01487044","phase":"","title":"A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema","status":"AVAILABLE","sponsor":"Retina Institute of Hawaii","startDate":"","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT01487070","phase":"PHASE1","title":"A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Retina Institute of Hawaii","startDate":"2011-04","conditions":"PDR","enrollment":5},{"nctId":"NCT01486771","phase":"PHASE4","title":"Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)","status":"UNKNOWN","sponsor":"Valley Retina Institute","startDate":"2007-11","conditions":"Proliferative Diabetic Retinopathy","enrollment":30},{"nctId":"NCT00788177","phase":"PHASE3","title":"Subretinal Macugen® for Neovascular Age-Related Macular Degeneration","status":"UNKNOWN","sponsor":"Klinikum Ludwigshafen","startDate":"2008-11","conditions":"Age-related Macular Degeneration","enrollment":10},{"nctId":"NCT00735943","phase":"","title":"Macugen Observational Study","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Vascular Endothelial Growth Factor, Macular Degeneration","enrollment":22},{"nctId":"NCT00239928","phase":"PHASE2","title":"Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Macular Degeneration","enrollment":61},{"nctId":"NCT01245387","phase":"","title":"Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-08","conditions":"Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration","enrollment":1001},{"nctId":"NCT00324116","phase":"PHASE4","title":"Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-07","conditions":"Macular Degeneration","enrollment":81},{"nctId":"NCT00531336","phase":"PHASE2","title":"MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen","status":"COMPLETED","sponsor":"The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery","startDate":"2006-07","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT00295828","phase":"PHASE1","title":"A Pilot Study for the Treatment of Iris Neovascularization With Macugen","status":"COMPLETED","sponsor":"Hermann Eye Center","startDate":"2006-01","conditions":"Iris Neovascularization, Diabetic Retinopathy","enrollment":10},{"nctId":"NCT00358423","phase":"PHASE1, PHASE2","title":"The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2006-07","conditions":"Cystoid Macular Edema","enrollment":1},{"nctId":"NCT00346983","phase":"PHASE1, PHASE2","title":"Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2006-06","conditions":"Cystoid Macular Edema","enrollment":4},{"nctId":"NCT00150202","phase":"PHASE3","title":"Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":"Macular Degeneration","enrollment":90},{"nctId":"NCT00088283","phase":"PHASE2","title":"Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-05","conditions":"Retinal Vein Occlusion","enrollment":90},{"nctId":"NCT00312351","phase":"PHASE4","title":"A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2006-04","conditions":"Macular Degeneration","enrollment":262},{"nctId":"NCT00354445","phase":"PHASE4","title":"A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD","status":"UNKNOWN","sponsor":"Eyetech Pharmaceuticals","startDate":"2006-06","conditions":"Age-Related Macular Degeneration (AMD)","enrollment":1000},{"nctId":"NCT00134667","phase":"PHASE4","title":"Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2005-03","conditions":"Age-Related Macular Degeneration","enrollment":360},{"nctId":"NCT00272766","phase":"NA","title":"Macugen for Histoplasmosis","status":"TERMINATED","sponsor":"Barnes Retina Institute","startDate":"2006-02","conditions":"Ocular Histoplasmosis, Choroidal Neovascularization","enrollment":24},{"nctId":"NCT00321997","phase":"PHASE2, PHASE3","title":"A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2001-05","conditions":"Age-Related Macular Degeneration","enrollment":540},{"nctId":"NCT00087763","phase":"PHASE2","title":"Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-03","conditions":"Macular Degeneration","enrollment":135},{"nctId":"NCT00215670","phase":"PHASE2, PHASE3","title":"Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2002-11","conditions":"Age-Related Macular Degeneration","enrollment":125},{"nctId":"NCT00040313","phase":"PHASE2","title":"Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2002-10","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00088192","phase":"NA","title":"Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Eyetech Pharmaceuticals","startDate":"2004-07","conditions":"Macular Degeneration","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ADHESION"},{"count":1,"reaction":"CATARACT"},{"count":1,"reaction":"DIABETES MELLITUS"},{"count":1,"reaction":"DRUG HYPERSENSITIVITY"},{"count":1,"reaction":"INTERMEDIATE UVEITIS"},{"count":1,"reaction":"IRIDOCYCLITIS"},{"count":1,"reaction":"VITREOUS DETACHMENT"}],"_approvalHistory":[],"publicationCount":154,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Macugen® (pegaptanib sodium)"],"phase":"marketed","status":"active","brandName":"Macugen (Pegaptanib Sodium)","genericName":"Macugen (Pegaptanib Sodium)","companyName":"Retina Institute of Hawaii","companyId":"retina-institute-of-hawaii","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegaptanib is an aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}